BioVie Inc Aktie News

BioVie Inc (NASDAQ:BIVI), a clinical-stage company focused on innovative drug therapies, announced today the approval of a clinical trial award of up to $13.1 million from the U.S. Department of Defense (DOD) to evaluate Bezisterim (NE3107) for treating neurological symptoms associated with long COVID.

Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID

BioVie Inc (NASDAQ:BIVI) announced that it has presented data showing its lead drug asset NE3107 may restore homeostasis via specific genes associated with dementia, metabolism and inflammation at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit held in Boston from April 23 to 25. Additionally, the company said that bezisterim has been approved as the generic name for NE3107 by...

CARSON CITY, Nev., April 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including neurological and neuro-degenerative disorders and liver disease, today announced that an oral presentation and poster revealing additional data on how bezisterim potentially...

Additionally, the Company announced approval of the non-proprietary name “bezisterim” for NE3107 Additionally, the Company announced approval of the non-proprietary name “bezisterim” for NE3107

ORLANDO, FL / ACCESSWIRE / April 12, 2024 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April 13, at 7 p.m. Eastern Time (ET).

SAN DIEGO , March 26, 2024 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in BioVie Inc. (NASDAQ: BIVI) shares. Investors, who purchased shares of BioVie Inc. (NASDAQ: BIVI) prior to August 2021 and continue to hold any of those shares, have also certain options and should contact the Shareholders Foundation at mail@shareholdersfounda...

NEW YORK, NY / ACCESSWIRE / March 19, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=71801&wire=1 or contact Joseph E. Levi, Esq.